{"id":41404,"date":"2025-09-15T16:12:46","date_gmt":"2025-09-15T08:12:46","guid":{"rendered":"https:\/\/flcube.com\/?p=41404"},"modified":"2025-09-15T16:12:47","modified_gmt":"2025-09-15T08:12:47","slug":"lion-tcr-secures-fda-approval-for-liocyx%e2%80%91m004-launching-phase-ib-ii-trial-in-chronic-hepatitis-b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41404","title":{"rendered":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB"},"content":{"rendered":"\n<p>In a landmark announcement, <strong>Lion TCR<\/strong> disclosed that the U.S. <strong>Food and Drug Administration (FDA)<\/strong> has granted approval to initiate a <strong>Phase Ib\/II clinical trial<\/strong> of its novel <strong>mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004<\/strong>, for the treatment of <strong>chronic hepatitis\u202fB (CHB)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-liocyx-m004-works\">How LioCyx\u2011M004 Works<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autologous Platform<\/strong>: The therapy employs a patient\u2019s own T cells, genetically reprogrammed with mRNA to express a T\u2011cell receptor (TCR) that specifically recognizes the hepatitis\u202fB surface antigen (HBsAg).<\/li>\n\n\n\n<li><strong>Targeted Cytotoxicity<\/strong>: Engineered T cells home to liver cells infected with HBV, selectively killing them while sparing healthy hepatocytes.<\/li>\n\n\n\n<li><strong>Transient, Safe Expression<\/strong>: The mRNA\u2011based approach delivers short\u2011lived TCR expression, reducing long\u2011term off\u2011target risks; multiple infusions further optimize safety and therapeutic benefit.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-in-class-achievement\">First\u2011In\u2011Class Achievement<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global First<\/strong>: LioCyx\u2011M004 is the <strong>first TCR\u2011T therapy<\/strong> approved by the FDA for chronic hepatitis\u202fB worldwide.<\/li>\n\n\n\n<li><strong>Fast\u2011Track Designation<\/strong>: It also becomes the <strong>first HBV\u2011specific TCR\u2011T therapy<\/strong> to receive FDA Fast\u2011Track status, expediting development and review timelines.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-chb-treatment\">Implications for CHB Treatment<\/h2>\n\n\n\n<p>Chronic hepatitis\u202fB remains a leading cause of liver cirrhosis and hepatocellular carcinoma, yet current antiviral regimens rarely achieve functional cure. LioCyx\u2011M004 offers a precision immunotherapy that could eradicate infected hepatocytes, potentially transforming the therapeutic landscape for HBV\u2011related liver disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>Lion\u202fTCR will commence the Phase\u202fIb\/II study in the first quarter of 2026, enrolling patients with treatment\u2011na\u00efve or treatment\u2011experienced CHB. The company anticipates pivotal data collection by 2028, with the possibility of accelerated regulatory pathways should the trial demonstrate robust safety and efficacy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41406,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[21,77,1708,89],"class_list":["post-41404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-car-t","tag-cell-therapy","tag-lion-tcr","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA) has granted approval to initiate a Phase Ib\/II clinical trial of its novel mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004, for the treatment of chronic hepatitis\u202fB (CHB).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41404\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB\" \/>\n<meta property=\"og:description\" content=\"In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA) has granted approval to initiate a Phase Ib\/II clinical trial of its novel mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004, for the treatment of chronic hepatitis\u202fB (CHB).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41404\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T08:12:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-15T08:12:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\\\/II Trial in Chronic Hepatitis\u202fB\",\"datePublished\":\"2025-09-15T08:12:46+00:00\",\"dateModified\":\"2025-09-15T08:12:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1506.webp\",\"keywords\":[\"CAR-T\",\"Cell-therapy\",\"Lion TCR\",\"Viral hepatitis\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41404#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41404\",\"name\":\"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\\\/II Trial in Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1506.webp\",\"datePublished\":\"2025-09-15T08:12:46+00:00\",\"dateModified\":\"2025-09-15T08:12:47+00:00\",\"description\":\"In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA) has granted approval to initiate a Phase Ib\\\/II clinical trial of its novel mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004, for the treatment of chronic hepatitis\u202fB (CHB).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41404\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\\\/II Trial in Chronic Hepatitis\u202fB\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41404#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\\\/II Trial in Chronic Hepatitis\u202fB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry","description":"In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA) has granted approval to initiate a Phase Ib\/II clinical trial of its novel mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004, for the treatment of chronic hepatitis\u202fB (CHB).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41404","og_locale":"en_US","og_type":"article","og_title":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB","og_description":"In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA) has granted approval to initiate a Phase Ib\/II clinical trial of its novel mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004, for the treatment of chronic hepatitis\u202fB (CHB).","og_url":"https:\/\/flcube.com\/?p=41404","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-15T08:12:46+00:00","article_modified_time":"2025-09-15T08:12:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41404#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41404"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB","datePublished":"2025-09-15T08:12:46+00:00","dateModified":"2025-09-15T08:12:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41404"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41404#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp","keywords":["CAR-T","Cell-therapy","Lion TCR","Viral hepatitis"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41404#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41404","url":"https:\/\/flcube.com\/?p=41404","name":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41404#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41404#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp","datePublished":"2025-09-15T08:12:46+00:00","dateModified":"2025-09-15T08:12:47+00:00","description":"In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA) has granted approval to initiate a Phase Ib\/II clinical trial of its novel mRNA\u2011encoded TCR\u2011T cell therapy, LioCyx\u2011M004, for the treatment of chronic hepatitis\u202fB (CHB).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41404#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41404"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41404#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp","width":1080,"height":608,"caption":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41404#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lion\u202fTCR Secures FDA Approval for LioCyx\u2011M004, Launching Phase\u202fIb\/II Trial in Chronic Hepatitis\u202fB"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41404"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41404\/revisions"}],"predecessor-version":[{"id":41407,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41404\/revisions\/41407"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41406"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}